SpotLIGHT ⎪ RHEUMATIC HEART DISEASE
Light AI QuickScan™ Strep A and The Prevention of Rheumatic Heart Disease
David Talan, MD
A sore throat might seem like a minor illness, but in some cases, it can also lead to long-term heart damage
Rheumatic Heart Disease (RHD) is a serious, yet preventable, condition that begins with an infection caused by Group A Streptococcus (GAS), the bacteria responsible for strep throat and certain skin infections.
These infections are often common in childhood and spread easily through respiratory droplets, particularly in crowded environments, such as schools or shared living spaces. (WHO, 2025; CDC, 2025)
When strep throat infections are diagnosed and treated early, the risk of serious complications can be greatly reduced. But when access to testing or treatment is restricted or delayed, the consequences can extend far beyond the initial infection.
The pathway from a sore throat to heart disease occurs rapidly in multiple disease stages.
Rheumatic Heart Disease develops after acute rheumatic fever, an inflammatory reaction that can occur shortly after untreated or undertreated streptococcal infection, such as bacterial strep throat, Group A Streptococcal infection (GAS).
Rather than being caused directly by bacteria damaging the heart, Rheumatic Fever occurs when the body’s immune system reacts to the earlier infection and mistakenly attacks healthy tissues.
This inflammation can affect several parts of the body, including the joints, skin, brain, and heart. When the heart is involved, the valves can become scarred and permanently damaged.
Over time, this damage can lead to Rheumatic Heart Disease, which may result in heart failure, stroke, or the need for surgical valve repair or replacement.
The Progression of Rheumatic Heart Disease Typically Follows a Sequence:
Group A Streptococcus infection (often strep throat)
Untreated or undertreated infection triggers an immune reaction
Acute Rheumatic Fever develops weeks later
Inflammation damages heart valves
Chronic Rheumatic Heart Disease emerges
IMPORTANT:
Viral pharyngitis should not be treated with antibiotic because viruses do not respond to antibacterial drugs, meaning antibiotics offer no symptom relief, no faster recovery, and no prevention of complications in these cases.
When antibiotics are taken unnecessarly, patients are exposed to adverse issues, including gastrointestinal resistance, which makes future bacterial infections harder to treat and less predictable.
In contrast, failure to appropriately treat GAS, can lead to serious but preventable complications that remain clinically relevant in Western countries including acute Rheumatic Fever with resulting Rheumatic Heart Disease, post-streptococcal glomerulonephritis, post-streptococcal reactive arthritis and suppurative infections such as peritonsillar abbess or cervical lymphadenitis.
Despite being preventable, Rheumatic Heart Disease continues to affect millions of people worldwide.
The World Health Organization describes the condition as a major global health issue and notes that it begins with a Strep infection that spreads easily between people, particularly among children.
Globally:“The most effective point to intervene in this chain is early diagnosis and treatment of the initial GAS infection.”
David Talan, MD
Preventing Rheumatic Heart Disease starts with recognizing and confirming strep infections early.
When healthcare providers can quickly determine whether a sore throat is caused by bacteria, they can prescribe appropriate treatment and reduce the risk of complications.
Antibiotics given for confirmed strep throat infections can significantly reduce the likelihood of developing acute rheumatic fever.
Accurate and early testing also help address another global health challenge, Antimicrobial Resistance (AMR).
Many sore throats are caused by viruses rather than bacteria, meaning antibiotics are not needed. Identifying the cause of infection early helps ensure antibiotics are used only when appropriate.
In other words, better diagnostics support both prevention and responsible Antibiotic Stewardship.
This is where our emerging technologies play a transformative role.
Light AI is developing smart device-based diagnostic tools powered by artificial intelligence, designed to help identify infections closer to the point-of-care.
The vision behind this work is to make reliable health insights more accessible, particularly in settings where laboratory infrastructure or rapid testing may be limited.
By enabling earlier identification of bacterial infections such as GAS, technology has the potential to:
Rheumatic Heart Disease illustrates a broader reality in global health. Sometimes the most serious outcomes begin with a condition that is easily treatable.
Improving access to testing and diagnosis can help healthcare systems:
By bringing diagnostic insights closer to where care happens, new technologies may help close the gap between symptoms and treatment.
For millions of people worldwide, the difference between a temporary infection and lifelong heart disease comes down to timing.
When infections are detected early and treated appropriately, the pathway from Strep Throat to Rheumatic Heart Disease can be avoided with early detection and treatment.
At Light AI, the mission is aligned with that goal: to develop technologies that make timely, accessible digital software tools for the healthcare provider’s clinic decision support through AI machine learning cloud-based diagnostics, helping communities and healthcare systems respond earlier to infection.
Because sometimes preventing lifelong heart disease starts with something as simple as recognizing a sore throat from a Step A infection and having the tools to understand it quickly.
References
Dr. David A. Talan is board-certified in Internal Medicine, Emergency Medicine, and Infectious Diseases, and serves as Professor of Medicine in Residence (Emeritus) at UCLA and the University of Iowa. He has chaired the Olive View-UCLA Department of Emergency Medicine and is currently on the faculty at UCLA Ronald Reagan Medical Center.
Dr. Talan’s research focuses on acute infections, emergency department-based surveillance, and epidemiological research of emerging infections.
He has numerous publications in prestigious journals, and his work has significantly influenced the management of infectious diseases.